M. Kraus & CO Abb Vie Inc. Transaction History

M. Kraus & CO

$291 Million
Q1 2025

A detailed history of M. Kraus & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, M. Kraus & CO holds 39,689 shares of ABBV stock, worth $7.51 Million. This represents 2.86% of its overall portfolio holdings.

Number of Shares

39,689

Previous 40,514 2.04%

Holding current value

$7.51 Million

Previous $7.2 Million 15.5%

% of portfolio

2.86%

Previous 2.39%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 17, 2025	SELL	$169.2 - $216.66 $139,590 - $178,744	-825 Reduced 2.04%	39,689 $8.32 Million
Q4 2024 Jan 14, 2025	BUY	$164.99 - $203.87 $61,211 - $75,635	371 Added 0.92%	40,514 $7.2 Million
Q3 2024 Oct 11, 2024	SELL	$163.84 - $199.33 $192,512 - $234,212	-1,175 Reduced 2.84%	40,143 $7.93 Million
Q2 2024 Jul 10, 2024	SELL	$154.79 - $180.76 $20,122 - $23,498	-130 Reduced 0.31%	41,318 $7.09 Million
Q1 2024 Apr 10, 2024	BUY	$159.82 - $182.1 $186,190 - $212,146	1,165 Added 2.89%	41,448 $7.55 Million
Q4 2023 Jan 10, 2024	BUY	$137.6 - $154.97 $325,148 - $366,194	2,363 Added 6.23%	40,283 $6.24 Million
Q3 2023 Oct 16, 2023	SELL	$133.59 - $154.65 $94,180 - $109,028	-705 Reduced 1.83%	37,920 $5.65 Million
Q2 2023 Jul 14, 2023	SELL	$132.51 - $164.9 $102,960 - $128,127	-777 Reduced 1.97%	38,625 $5.2 Million
Q1 2023 Apr 18, 2023	SELL	$144.61 - $166.54 $17,063 - $19,651	-118 Reduced 0.3%	39,402 $6.28 Million
Q4 2022 Jan 25, 2023	SELL	$138.31 - $165.87 $5,255 - $6,303	-38 Reduced 0.1%	39,520 $0
Q3 2022 Oct 27, 2022	SELL	$134.21 - $153.93 $1,342 - $1,539	-10 Reduced 0.03%	39,558 $5.31 Million
Q2 2022 Jul 15, 2022	SELL	$137.62 - $174.96 $688 - $874	-5 Reduced 0.01%	39,568 $6.06 Million
Q1 2022 Apr 18, 2022	BUY	$131.98 - $163.75 $91,726 - $113,806	695 Added 1.79%	39,573 $6.42 Million
Q4 2021 Jan 19, 2022	SELL	$107.43 - $135.93 $93,034 - $117,715	-866 Reduced 2.18%	38,878 $5.26 Million
Q3 2021 Oct 18, 2021	BUY	$106.4 - $120.78 $212 - $241	2 Added 0.01%	39,744 $4.29 Million
Q2 2021 Jul 21, 2021	SELL	$105.21 - $117.21 $71,542 - $79,702	-680 Reduced 1.68%	39,742 $4.48 Million
Q1 2021 Apr 19, 2021	SELL	$102.3 - $112.62 $55,037 - $60,589	-538 Reduced 1.31%	40,422 $4.37 Million
Q4 2020 Jan 13, 2021	SELL	$80.49 - $108.67 $65,357 - $88,240	-812 Reduced 1.94%	40,960 $4.39 Million
Q3 2020 Oct 09, 2020	SELL	$85.91 - $100.83 $13,917 - $16,334	-162 Reduced 0.39%	41,772 $3.66 Million
Q2 2020 Jul 23, 2020	SELL	$73.37 - $98.18 $17,241 - $23,072	-235 Reduced 0.56%	41,934 $4.12 Million
Q1 2020 Apr 14, 2020	SELL	$64.5 - $97.79 $85,011 - $128,887	-1,318 Reduced 3.03%	42,169 $3.21 Million
Q4 2019 Jan 15, 2020	SELL	$72.13 - $90.25 $22,071 - $27,616	-306 Reduced 0.7%	43,487 $3.85 Million
Q3 2019 Oct 10, 2019	SELL	$62.98 - $75.72 $156,442 - $188,088	-2,484 Reduced 5.37%	43,793 $3.32 Million
Q2 2019 Jul 17, 2019	SELL	$65.7 - $83.98 $105,711 - $135,123	-1,609 Reduced 3.36%	46,277 $3.37 Million
Q1 2019 Apr 15, 2019	SELL	$77.14 - $90.79 $121,186 - $142,631	-1,571 Reduced 3.18%	47,886 $3.86 Million
Q4 2018 Jan 15, 2019	SELL	$77.85 - $96.01 $516,923 - $637,506	-6,640 Reduced 11.84%	49,457 $4.56 Million
Q3 2018 Oct 23, 2018	SELL	$88.91 - $98.84 $119,850 - $133,236	-1,348 Reduced 2.35%	56,097 $5.31 Million
Q2 2018 Jul 11, 2018	SELL	$89.78 - $106.23 $806,493 - $954,264	-8,983 Reduced 13.52%	57,445 $5.32 Million
Q1 2018 Apr 19, 2018	SELL	$92.01 - $123.21 $72,687 - $97,335	-790 Reduced 1.18%	66,428 $6.29 Million
Q4 2017 Jan 18, 2018	SELL	$89.56 - $98.21 $142,400 - $156,153	-1,590 Reduced 2.31%	67,218 $6.5 Million
Q3 2017 Oct 17, 2017	BUY	$69.85 - $89.22 $4.81 Million - $6.14 Million	68,808	68,808 $6.11 Million

Others Institutions Holding ABBV

# of Institutions

4,270

Shares Held

1.27B

Call Options Held

18.2M

Put Options Held

15.5M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $335B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M. Kraus & CO, based on Form 13F filings with the SEC.

News

Stay updated on M. Kraus & CO with notifications on news.

Account